Vabysmo(faricimab)
Vabysmo (faricimab) is an antibody pharmaceutical. Faricimab was first approved as Vabysmo on 2022-01-28. It is used to treat diabetic retinopathy in the USA. It has been approved in Europe to treat diabetes complications, macular edema, and wet macular degeneration. The pharmaceutical is active against vascular endothelial growth factor A, long form and angiopoietin-2. In addition, it is known to target Vascular permeability factor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Vabysmo
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| vabysmo | Biologic Licensing Application | 2024-12-02 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| diabetic retinopathy | EFO_0003770 | D003930 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg |
Clinical
Clinical Trials
47 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Macular edema | D008269 | — | — | — | 2 | 6 | 1 | 3 | 12 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | 1 | 1 | 4 | 1 | 3 | 10 |
| Edema | D004487 | — | R60.9 | — | 1 | 6 | 1 | — | 8 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Retinal vein occlusion | D012170 | EFO_1001157 | H34.81 | — | — | 2 | — | 2 | 4 |
| Wet macular degeneration | D057135 | EFO_0004683 | — | — | — | 3 | — | — | 3 |
| Retinal neovascularization | D015861 | — | H35.05 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Choroidal neovascularization | D020256 | — | — | — | 2 | — | — | — | 2 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Faricimab |
| INN | faricimab |
| Description | Faricimab, sold under the brand name Vabysmo, is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Faricimab is the first bispecific monoclonal antibody to target both vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2). By targeting these pathways, faricimab stabilizes blood vessels in the retina. It is given by intravitreal injection (injection into the eye) by an ophthalmologist.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297750 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB15303 |
| UNII ID | QC4F7FKK7I (ChemIDplus, GSRS) |
Target
Agency Approved
VEGFA
VEGFA
ANGPT2
ANGPT2
Organism
Homo sapiens
Gene name
VEGFA
Gene synonyms
VEGF
NCBI Gene ID
Protein name
vascular endothelial growth factor A, long form
Protein synonyms
vascular endothelial growth factor A121, vascular endothelial growth factor A165, Vascular permeability factor, VPF
Uniprot ID
Mouse ortholog
Vegfa (22339)
vascular endothelial growth factor A, long form (Q6WZL9)
Alternate
VEGFA
VEGFA
Organism
Homo sapiens
Gene name
VEGFA
Gene synonyms
NCBI Gene ID
—
Protein name
Vascular permeability factor
Protein synonyms
Uniprot ID
Mouse ortholog
—
—
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Vabysmo – Roche
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,187 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,491 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use